SCHEMBL4575997

SCHEMBL4575997

O=S(=O)(Cl)Cl.O=[N+]([O-])c1ccc(F)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPB1 P04792 3/20 0.62
POLB P06746 1/20 0.56
CA1 P00915 7/20 0.52
CA2 P00918 7/20 0.52
CA9 Q16790 5/20 0.52
CA5A P35218 3/20 0.52
CA12 O43570 3/20 0.52
CA14 Q9ULX7 3/20 0.52
CA3 P07451 2/20 0.52
CA4 P22748 2/20 0.52
CA6 P23280 2/20 0.52
CA7 P43166 2/20 0.52
CA13 Q8N1Q1 2/20 0.52
CA5B Q9Y2D0 2/20 0.52
GAA P10253 2/20 0.51
KCNJ1 P48048 1/20 0.49
KCNH2 Q12809 1/20 0.49
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
MMP1 P03956 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7026994 0.89 HSPB1 (0.75) HSPB1POLBCA1CA2CA9
SCHEMBL536 0.89 HSPB1 (0.75) HSPB1POLBCA1CA2CA9
Fluoride SCHEMBL4551986 0.86 HSPB1 (0.72) HSPB1POLBGAAKCNJ1KCNH2
Water SCHEMBL28147677 0.86 HSPB1 (0.72) HSPB1POLBGAAKCNJ1KCNH2
Fluoride SCHEMBL4551988 0.86 HSPB1 (0.72) HSPB1POLBGAAKCNJ1KCNH2
SCHEMBL28001935 0.86 HSPB1 (0.72) HSPB1POLBGAAKCNJ1KCNH2
SCHEMBL6038264 0.85 HSPB1 (0.60) HSPB1POLBCA1CA2CA9
Formaldehyde SCHEMBL28237406 0.84 HSPB1 (0.69) HSPB1POLBGAAKCNJ1KCNH2
Ethylene SCHEMBL27864908 0.84 HSPB1 (0.69) HSPB1POLBGAAKCNJ1KCNH2
Ethane SCHEMBL28251595 0.84 HSPB1 (0.69) HSPB1POLBGAAKCNJ1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137703-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER CANCER RESEARCH TECH LIMITED (GB) 2026-05-21 US disclosed
EP-4612148-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER Cancer Research Technology Limited (GB) 2025-09-10 EP disclosed
WO-2024094963-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-05-10 WO disclosed
CN-109153642-A Indoles and azaindole halogenated allylamine derivatives inhibitors of lysyloxidase and application thereof 法玛西斯有限公司 2019-01-04 CN disclosed
CN-109071533-A Halogenated allylamine indoles and 7-azaindole derivatives inhibitor of lysyloxidase and application thereof 法玛西斯有限公司 2018-12-21 CN disclosed
CN-108698982-A FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF 日产化学工业株式会社 2018-10-23 CN disclosed
CN-107257788-A Benzenesulfonamide derivatives as inverse agonists of the retinoid-related orphan receptor gamma (ROR gamma (t)) 盖尔德马研究及发展公司 2017-10-17 CN disclosed
CN-107207467-A 2, 4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG 癌症研究科技有限公司 2017-09-26 CN disclosed
CN-102036967-B As 5-HT6Arylsulfonyl pyrazoline carboxamidine derivatives as antagonists ABBOTT HEALTHCARE PRODUCTS B.V. (NL) 2014-10-15 CN disclosed
CN-104003937-A Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists ABBOTT HEALTHCARE PRODUCTS BV 2014-08-27 CN disclosed
US-7393849-B2 Substituted sulfonamides and ureas useful for inhibiting kinase activity AVENTIS PHARMACEUTICALS INC. (US) 2008-07-01 US disclosed
US-7323457-B2 Substituted sulfonamides and ureas useful for inhibiting kinase activity AVENTIS PHARMACEUTICALS INC. (US) 2008-01-29 US disclosed
US-20070208008-A1 SUBSTITUTED SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY AVENTIS PHARMACEUTICALS INC. (US) 2007-09-06 US disclosed
US-20070191347-A1 SUBSTITUTED SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY AVENTIS PHARMACEUTICALS INC. 2007-08-16 US disclosed
US-7223763-B2 Substituted sulfonamides and ureas useful for inhibiting kinase activity AVENTIS PHARMACEUTICALS INC. (US) 2007-05-29 US disclosed
EP-1423373-B1 SUBSTITUTED AMIDES, SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY AVENTIS PHARMA INC (US) 2005-10-19 EP disclosed
US-20040204582-A1 Substituted sulfonamides and ureas useful for inhibiting kinase activity AVENTIS PHARMACEUTICALS INC. 2004-10-14 US disclosed
US-6777577-B2 ANTICANCER AGENTS; ANTIDIABETIC AGENTS, ANTICHOLESTEROL AGENTS, CARDIOVASCULAR DISORDERS, OSTEOPOROSIS AVENTIS PHARMACEUTICALS INC. 2004-08-17 US disclosed
US-20030087832-A1 Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity AVENTIS PHARMACEUTICALS INC. 2003-05-08 US disclosed
US-20030045480-A1 Method of treating hyperresorptive bone disorders ARIAD PHARMACEUTICALS, INC. 2003-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208008-A1 SUBSTITUTED SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY CHUK, SRC, DSTYK HSPB1 2127/4885POLB 3077/4885CA1 2680/4885
US-20040204582-A1 Substituted sulfonamides and ureas useful for inhibiting kinase activity CHUK, SRC, DSTYK HSPB1 1969/4885POLB 3036/4885CA1 2649/4885
US-20260137703-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER EGFR, KRAS, O60361 HSPB1 1623/4885POLB 458/4885CA1 3692/4885
US-20030045480-A1 Method of treating hyperresorptive bone disorders SRC, GRB2, ACP1 HSPB1 453/4885POLB 4362/4885CA1 3509/4885
US-20070191347-A1 SUBSTITUTED SULFONAMIDES AND UREAS USEFUL FOR INHIBITING KINASE ACTIVITY CHUK, SRC, DSTYK HSPB1 2127/4885POLB 3077/4885CA1 2680/4885
US-20030087832-A1 Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity SRC, CHUK, DSTYK HSPB1 2164/4885POLB 3630/4885CA1 2046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.